POST Online Media Lite Edition



 

Nestlé to buy aesthetic dermatology assets for $1.4 billion

Staff writer |
On 11th February 2014, Nestlé announced it would extend its activities to include the field of specialised medical skin treatments through the creation of Nestlé Skin Health S.A.

Article continues below






Now Nestlé is announcing it will reinforce Nestlé Skin Health with the acquisition from the Canadian firm Valeant Pharmaceuticals International of the full rights to commercialise several key aesthetic dermatology products in the US and Canada for $1.4 billion in cash. The two markets together represent more than half of the fast-growing medical aesthetics market around the world. Galderma already commercialises the products included in this transaction outside those markets.

The foundation for the company would be Galderma, the 50/50 joint venture with L’Oréal, which would become fully-owned by Nestlé. Bübchen, our existing infant skincare business would be merged into the new entity. The acquisition of Galderma is awaiting final regulatory clearance.

Nestlé is acquiring the full rights to commercialise in the US and Canada Restylane, Perlane and Emervel, products used for corrective facial aesthetic treatments, and Dysport, an aesthetic dermatology treatment. It will also acquire the full rights to Sculptra, a unique treatment for aesthetic and medical uses in the US, Canada and many markets around the world.

The transaction is subject to regulatory approval and customary closing conditions.


What to read next

Nestlé reorganizes infant nutrition business
Nestlé chooses Kuehne + Nagel Netherlands as its logistics partner
Nestlé and R&R to create Froneri joint venture